Prestige Consumer Healthcare Inc.
A maker of over-the-counter health and personal care products sold in drugstores, supermarkets, and online, with familiar names like Dramamine (motion sickness), Monistat (women's health), Clear Eyes, BC, and Goody's pain powders. It was born in 1996 from a three-way merger of Medtech Products, Prestige Brands International, and the Spic and Span Company, and it built its lineup by buying well-loved but neglected brands from bigger firms. Fun fact: BC and Goody's headache powders began as laborer favorites in North Carolina's textile and tobacco fields, invented at a Durham drugstore in 1906.
10-Q · Quarter ended Jun 30, 2026 · SEC filing ↗
returned to growth after a year of decline, but the cost of that growth showed up immediately in margins. Revenue rose 6.5% to $265.7 million, driven by the newly acquired Breathe Right and Dimetapp brands, while fell 5.0 points to 51.3% as the company absorbed costs to optimize its new Canadian manufacturing plant and wrote up acquired . The acquisition is adding revenue, but the integration is still a drag on earnings.
Q1 FY2027 revenue rose 6.5% to $265.7M driven by the Breathe Right acquisition, while gross margin fell to 51.3% on integration costs.
For quantitative and qualitative disclosures about market risk, see Item 7a. "Quantitative and Qualitative Disclosures About Market Risk" of our Annual Report on Form 10-K for the year ended March 31, 2026. Our exposures to market risk have not changed materially since March 31,…
For quantitative and qualitative disclosures about market risk, see Item 7a. "Quantitative and Qualitative Disclosures About Market Risk" of our Annual Report on Form 10-K for the year ended March 31, 2026. Our exposures to market risk have not changed materially since March 31, 2026.
Read original filing text →Director Nominee For Withheld Broker Non-Votes Ronald M. Lombardi 45,785,872 1,716,653 564,694 John E. Byom 43,227,907 2,274,618 564,694 Celeste A. Clark 43,610,994 1,891,531 564,694 James C. D'Arecca 45,123,407 379,118 564,694 John F. Kelly 43,800,823 1,701,702 564,694 Dawn M.…
Director Nominee For Withheld Broker Non-Votes Ronald M. Lombardi 45,785,872 1,716,653 564,694 John E. Byom 43,227,907 2,274,618 564,694 Celeste A. Clark 43,610,994 1,891,531 564,694 James C. D'Arecca 45,123,407 379,118 564,694 John F. Kelly 43,800,823 1,701,702 564,694 Dawn M. Zier 43,959,205 1,543,320 564,694 Item 2 – Non-binding resolution to approve the compensation of our named executive officers as disclosed in our Proxy Statement. For Against Abstentions Broker Non-Votes 43,638,531 1,852,816 11,178 564,694 32
Read original filing text →You should carefully consider the risk factors discussed in Part I, Item 1A. "Risk Factors" in our Annual Report on Form 10-K for the year ended March 31, 2026, which could materially affect our business, financial condition or results of operations. The risk factors described i…
You should carefully consider the risk factors discussed in Part I, Item 1A. "Risk Factors" in our Annual Report on Form 10-K for the year ended March 31, 2026, which could materially affect our business, financial condition or results of operations. The risk factors described in our Annual Report on Form 10-K have not materially changed in the period covered by this Quarterly Report on Form 10-Q, but such risks are not the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and results of operations. Our quarterly operating results and revenues may fluctuate as a result of any of these or other factors. Accordingly, results for any one quarter are not necessarily indicative of results to be expected for any other quarter or for any year, and revenues for any particular future period may decrease. In the future, operating results may fall below the expectations of securities analysts and investors. In that event, the market price of our outstanding securities could be adversely impacted. 31
Read original filing text →